'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice - PubMed (original) (raw)
'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice
J Rataud et al. Brain Res. 1991.
Abstract
The effects of systemic treatment with the CCK-B receptor antagonist L-365,260, its 3S-(-) enantiomer and the CCK-A receptor antagonist devazepide were assessed in the plus-maze procedure in mice. L-365,260 (1-1000 micrograms.kg-1 i.p.) produced a dose-dependent increase in the percentage of entries into, and the percentage of time spent in the open arms. Total arm entry was not consistently modified. Neither the 3S-(-) enantiomer of L-365,260 nor devazepide (both administered at 100-10,000 micrograms.kg-1) enhanced the exploratory behavior of mice. These results suggest that CCK-B, rather than CCK-A antagonists may possess 'anxiolytic' properties in mice.
Similar articles
- Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.
Vasar E, Lang A, Harro J, Bourin M, Bradwejn J. Vasar E, et al. Neuropharmacology. 1994 Jun;33(6):729-35. doi: 10.1016/0028-3908(94)90112-0. Neuropharmacology. 1994. PMID: 7936110 - Anti-exploratory effect of N-methyl-D-aspartate in elevated plus-maze. Involvement of NMDA and CCK receptors.
Vasar E, Harro J, Lang A, Soosaar A, Oöpik T, Kôks S, Sihver S, Volke V. Vasar E, et al. Eur Neuropsychopharmacol. 1993 Mar;3(1):63-73. doi: 10.1016/0924-977x(93)90296-x. Eur Neuropsychopharmacol. 1993. PMID: 8471831 - Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats.
Männistö PT, Lang A, Harro J, Peuranen E, Bradwejn J, Vasar E. Männistö PT, et al. Naunyn Schmiedebergs Arch Pharmacol. 1994 May;349(5):478-84. doi: 10.1007/BF00169136. Naunyn Schmiedebergs Arch Pharmacol. 1994. PMID: 8065461 - CCK antagonists and CCK-monoamine interactions in the control of satiety.
Cooper SJ, Dourish CT, Clifton PG. Cooper SJ, et al. Am J Clin Nutr. 1992 Jan;55(1 Suppl):291S-295S. doi: 10.1093/ajcn/55.1.291s. Am J Clin Nutr. 1992. PMID: 1728842 Review. - [Cholecystokinin antagonists: anxiolytic drugs of the future].
Bourin M, Bradwejn J. Bourin M, et al. Pathol Biol (Paris). 1992 Mar;40(3):215-7. Pathol Biol (Paris). 1992. PMID: 1608663 Review. French. No abstract available.
Cited by
- Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test.
Dooley DJ, Klamt I. Dooley DJ, et al. Psychopharmacology (Berl). 1993;112(4):452-4. doi: 10.1007/BF02244893. Psychopharmacology (Berl). 1993. PMID: 7871056 - Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats.
Charrier D, Dangoumau L, Puech AJ, Hamon M, Thiébot MH. Charrier D, et al. Psychopharmacology (Berl). 1995 Sep;121(1):127-34. doi: 10.1007/BF02245599. Psychopharmacology (Berl). 1995. PMID: 8539337 - Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice.
Barrachina MD, Martínez V, Wang L, Wei JY, Taché Y. Barrachina MD, et al. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10455-60. doi: 10.1073/pnas.94.19.10455. Proc Natl Acad Sci U S A. 1997. PMID: 9294232 Free PMC article. - Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice.
Johnson NJ, Rodgers RJ. Johnson NJ, et al. Psychopharmacology (Berl). 1996 Apr;124(4):355-64. doi: 10.1007/BF02247441. Psychopharmacology (Berl). 1996. PMID: 8739551 - Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs.
Dawson GR, Rupniak NM, Iversen SD, Curnow R, Tye S, Stanhope KJ, Tricklebank MD. Dawson GR, et al. Psychopharmacology (Berl). 1995 Sep;121(1):109-17. doi: 10.1007/BF02245597. Psychopharmacology (Berl). 1995. PMID: 8539335
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical